Perspective from Elizabeth Matzkin, MD, FAAOS
Disclosures: Chahla reports he has received education support from Arthrex and Smith & Nephew; consulting fees from DePuy Synthes Products, Linvatec and Smith & Nephew; speaking fees from Linvatec; hospitality payments from Medical Device Business Services, Medwest Associates and Stryker; and other support from ConMed and Ossur. Singh reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.
August 20, 2021
1 min read
Save

PRP may relieve pain, improve function in patients with knee OA

Perspective from Elizabeth Matzkin, MD, FAAOS
Disclosures: Chahla reports he has received education support from Arthrex and Smith & Nephew; consulting fees from DePuy Synthes Products, Linvatec and Smith & Nephew; speaking fees from Linvatec; hospitality payments from Medical Device Business Services, Medwest Associates and Stryker; and other support from ConMed and Ossur. Singh reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Published results showed platelet-rich plasma led to improved outcomes in patients with symptomatic knee osteoarthritis at a minimum of 6-months compared with plasma rich in growth factors, hyaluronic acid, corticosteroids and placebo.

Jorge A. Chahla, MD, PhD, Harsh Singh, BA, and colleagues performed a systematic review and developed a frequentist network meta-analysis to compare the effects of hyaluronic acid, corticosteroids, PRP, plasma rich in growth factors and placebo on patient-reported outcomes in patients with symptomatic knee OA. Researchers recorded mean or mean change from baseline and standard deviation for outcome scores regarding pain and function at the 6-month follow-up and converted this to either a VAS score for pain or WOMAC score for function.

All intra-articular treatments except corticosteroids had a statistically significant improvement in outcomes compared with placebo, according to results. Researchers found the compared with corticosteroids and placebo, PRP had a clinically meaningful difference in function-related improvement due to large effect sizes. Results showed plasma rich in growth factors had a significant improvement in outcomes compared with placebo due to large effect sizes. However, plasma rich in growth factors had a potentially clinically significant difference vs. placebo in pain evaluation, according to results. Researchers noted PRP had the highest probability of efficacy with regard to improvements in pain relief, function and both of these combined, followed by plasma rich in growth factors, hyaluronic acid, corticosteroids and placebo.

Jorge A. Chahla
Jorge A. Chahla
Harsh Singh
Harsh Singh

“With growing curiosity into the role of PRP in the treatment of degenerative orthopedic diseases, this study provides meaningful data to physicians and surgeons for long-term nonoperative management of knee osteoarthritis,” Chahla told Healio Orthopedics. “Patients with knee osteoarthritis may need close to 13 years of nonoperative management prior to end of life or total knee arthroplasty. As such, our results demonstrate the potential for PRP to become a mainstay in long-term management of knee osteoarthritis. Taking the results from this study, future studies can investigate the role of PRP and other injections in treatment of osteoarthritis of other joints.”

Reference:

www.jorgechahlamd.com/biologic-injections/